https://www.selleckchem.com/pr....oducts/plerixafor.ht
Safety profile is satisfactory. Thirteen serious adverse events were reported during the 28-week follow-up, none of which were related to Vi-DT. The seroconversion rate four weeks after the first dose was 100% (95% CI 98·3-10 in Vi-DT recipients and 7·0% (95% CI 2·8-16·7) in comparator recipients (p0·0001). Similarly, the seroconversion rate 4 weeks after the second dose was 98·2% (95% CI 93· 6-99·5) and 21·8% (95% CI 13·0-34·4) among Vi-DT and comparator groups, respectively (p0·0001). Anti-Vi IgG GMT was significantly hig
Like
Comment
Share
